A Trial to Evaluate the Safety and Efficacy of 2 Treatment Regimens of Aztreonam 75mg Powder and Solvent for Nebulizer Solution/ Aztreonam for Inhalation Solution (AZLI) in Pediatric Subjects with Cystic Fibrosis (CF) and New Onset Respiratory Tract Pseudomonas aeruginosa (PA) Infection/ Colonization

About this Study

This study will evaluate the safety and effectiveness of a 14-day course vs a 28-day course of Aztreonam (AZLI) in Cystic Fibrosis participants with new onset Pseudomonas aeruginosa (PA) infection.

Sponsor Protocol ID:GS-US-205-1850
IRB Number:2017-0246
Closed for Enrollment
Interventional
Phase 3
May 28, 2019
Eligibility Criteria
18 years old
Both Male and Female
No
Yes
No

Inclusion Criteria
  • Male or female aged 3 months to less than 18 years at screening. 
  • A negative serum pregnancy test is required for female subjects of child bearing potential who have a positive urine pregnancy test at screening. 
  • Lactating females must agree to discontinue nursing before administration of study drug. 
  • Subjects and/or parent/guardian must be able to give written informed consent prior to study related procedures.

Exclusion Criteria
  • Use of IV or inhaled antipseudomonal antibiotics within 2 years of Screening. 
  • Use of oral antipseudomonal antibiotics for a respiratory event within 30 days of study entry. 
  • History of lung transplantation. 
  • Administration of any investigational drug or device within 28 days prior to Screening. 
  • Hospitalization for a respiratory event within 30 days prior to Screening. 

Categories Click category to view its trials.
Genetics
Lungs/Breathing
Pediatrics
Participating Locations
Children’s of Mississippi Hospital - Blair E. Batson Tower
Contact Information
Contact Name: Takila Keys
Phone Number: 601-815-6250
Email: tkeys@umc.edu
Principal Investigator:Josey, David, M.D.
How to participate in our Clinical Trials